Close Menu

At a conference yesterday, Merck's Merv Turner said big pharma's problems are due to researchers, reports Science Insider. "Seventy-five cents of every dollar we spend on R&D goes to fund failure," Turner said. He added that Merck is undergoing "painful" restructuring after acquiring Schering-Plough and that one area that will likely be pared down is late-stage drug development -- though "nothing's safe from cuts."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
13
Sponsored by
Lexogen

This webinar will outline the use of targeted protein degradation (TPD) to understand transcriptional processes at a high kinetic resolution.